Back
Entrada Therapeutics Stock Price Chart
Why Private Investors Didn't Lose a Penny in the Market's Recent $1T Crash
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
24
TRDA
Entrada Therapeutics
Last Price:
$9.87
Seasonality Move:
1.7%
7 Day Trial
ALL ACCESS PASS
$
7
7 Nuclear Stocks to Buy Before They Surge
Get your report FREE today!-
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and TRDA is experiencing slight selling pressure.
Entrada Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 10.59 | Sell |
| 20-day SMA: | 10.98 | Sell |
| 50-day SMA: | 12.3 | Sell |
| 200-day SMA: | 15.64 | Sell |
| 8-day EMA: | 10.59 | Sell |
| 20-day EMA: | 11.1 | Sell |
| 50-day EMA: | 12.56 | Sell |
| 200-day EMA: | 14.83 | Sell |
Entrada Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.66 | Sell |
| Relative Strength Index (14 RSI): | 34.74 | Sell |
| Chaikin Money Flow: | -50375 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | ( - ) | Buy |
| Bollinger Bands (100): | ( - ) | Buy |
Entrada Therapeutics Technical Analysis
| Mar 13 | Mar 14 | Mar 17 | Mar 18 | Mar 19 | Mar 20 | Mar 21 | Mar 24 | Mar 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | ||||||||||
| 13 | 14 | 17 | 18 | 19 | 20 | 21 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Entrada Therapeutics Stock
Is Entrada Therapeutics Stock a Buy?
-
Entrada Therapeutics share price is 10.18 while TRDA 8-day simple moving average is 10.59, which is a Sell signal.
-
The stock price of TRDA is 10.18 while Entrada Therapeutics 20-day SMA is 10.98, which makes it a Sell.
-
Entrada Therapeutics 50-day simple moving average is 12.30 while TRDA share price is 10.18, making it a Sell technically.
-
TRDA stock price is 10.18 and Entrada Therapeutics 200-day simple moving average is 15.64, creating a Sell signal.
TRDA Technical Analysis vs Fundamental Analysis
Sell
24
Entrada Therapeutics (TRDA)
is a Sell
Is Entrada Therapeutics a Buy or a Sell?
-
Entrada Therapeutics stock is rated a SellThe current Entrada Therapeutics [TRDA] share price is $10.18. The Score for TRDA is 24, which is 52% below its historic median score of 50, and infers higher risk than normal.
Entrada Therapeutics Stock Info
Market Cap:
382.5M
Price in USD:
10.18
Share Volume:
66.9K
Entrada Therapeutics 52-Week Range
52-Week High:
21.79
52-Week Low:
10.08
Sell
24
Entrada Therapeutics (TRDA)
is a Sell
Entrada Therapeutics Share Price Forecast
-
What is the Entrada Therapeutics stock price today?The Entrada Therapeutics stock price is 10.18 USD today.
-
Will TRDA stock go up or go down?Entrada Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Entrada Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Entrada Therapeutics is overvalued.
Is Entrada Therapeutics Stock a Buy?
-
Entrada Therapeutics share price is 10.18 while TRDA 8-day exponential moving average is 10.59, which is a Sell signal.
-
The stock price of TRDA is 10.18 while Entrada Therapeutics 20-day EMA is 11.10, which makes it a Sell.
-
Entrada Therapeutics 50-day exponential moving average is 12.56 while TRDA share price is 10.18, making it a Sell technically.
-
TRDA stock price is 10.18 and Entrada Therapeutics 200-day simple moving average is 14.83, creating a Sell signal.
Fundamental Analysis of Entrada Therapeutics
Is Entrada Therapeutics a good investment?
-
Analysts estimate an earnings decrease this quarter of $0.14 per share, a decrease next quarter of $0.15 per share, a decrease this year of $4.02 per share, and a decrease next year of $0.30 per share.
Technical Analysis of Entrada Therapeutics
Should I short Entrada Therapeutics stock?
-
TRDA Moving Average Covergence Divergence (MACD) indicator is -0.66, suggesting Entrada Therapeutics is a Sell
-
Entrada Therapeutics Relative Strength Index (RSI) is 34.74, which suggest Entrada Therapeutics is oversold
-
The Bollinger Bands (25) for Entrada Therapeutics is ( - ), which suggest Entrada Therapeutics is a Buy
-
The Bollinger Bands (100) for Entrada Therapeutics is ( - ), which suggest Entrada Therapeutics is a Buy
* Entrada Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.